MIRAXIM

This brand name is authorized in Nigeria.

Active ingredients

The drug MIRAXIM contains one active pharmaceutical ingredient (API):

1	Cefuroxime UNII Z49QDT0J8Z - CEFUROXIME AXETIL
	Cefuroxime inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death.
	Read more about Cefuroxime

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
A11-1022	Capsule	Miraxim Capsules CAP 500 mg	Each capsule contains: Cefuroxime (as Cefuroxime Axetil) 500 mg	20/12/2019
B4-5533	Suspension	Miraxim Suspension SUSP 125 mg/5 mL 1 X 100ML	Miraxim Suspension B4-5533 Miraxim CEFUROXIME ANTIBIOTICS CEFUROXIME 125MG/5ML SUSPENSION X 100ML PRESCRIPTION ONLY MEDICINE TREATMENT OF SUSCEPTIBLE BACTERIA INFECTIONS MIRAFLASH NIGERIA LIMITED NIGERIA MIRAFLASH NIGERIA LIMITED NIGERIA 08/25/2022 08/24/2027	25/08/2022
B4-5537	Capsule	Miraxim Capsules CAP 250 mg 1 X 10	Miraxim Capsules B4-5537 Miraxim CEFUROXIME ANTIBIOTICS CEFUROXIME 250MG CAPSULES 1 X 10 PRESCRIPTION ONLY MEDICINE TREATMENT OF SUSCEPTIBLE BACTERIA INFECTIONS MIRAFLASH NIGERIA LIMITED NIGERIA MIRAFLASH NIGERIA LIMITED NIGERIA 08/25/2022 08/24/2027	25/08/2022

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01DC02	Cefuroxime	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01D Other beta-lactam antibacterials → J01DC Second-generation cephalosporins
Discover more medicines within J01DC02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	A11-0998, A11-1022, B4-5533, B4-5537